Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for VRDN

Show aggregate VRDN holdings

News associated with VRDN

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.78 Consensus Price Target from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month […] - 2025-08-29 03:04:50

Jefferies Financial Group Begins Coverage on Viridian Therapeutics (NASDAQ:VRDN)

Jefferies Financial Group started coverage on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a report published on Monday. The brokerage issued a buy rating and a $44.00 target price on the stock. A number of other equities research analysts have also recently commented on VRDN. Wells Fargo & Company decreased their target price […] - 2025-08-26 03:04:49

Deutsche Bank AG Reduces Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Deutsche Bank AG decreased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 396,808 shares of the company’s stock after selling 6,066 shares during the quarter. Deutsche Bank AG’s holdings in […] - 2025-08-17 05:14:56

TD Asset Management Inc Trims Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

TD Asset Management Inc lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 36.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,600 shares of the company’s stock after selling 18,600 shares during the quarter. TD Asset Management Inc’s […] - 2025-08-05 04:34:53

Analysts See 19% Gains Ahead For FHLC

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-14 09:54:06

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among […] - 2025-07-07 05:11:43

Rhumbline Advisers Buys 4,621 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rhumbline Advisers lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,559 shares of the company’s stock after acquiring an additional 4,621 shares during the quarter. Rhumbline Advisers’ […] - 2025-06-19 04:10:54

Squarepoint Ops LLC Lowers Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Squarepoint Ops LLC reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 23.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,251 shares of the company’s stock after selling 10,328 shares during the quarter. Squarepoint Ops LLC’s holdings in […] - 2025-06-04 05:06:50

Nuveen Asset Management LLC Has $13.06 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Nuveen Asset Management LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 681,012 shares of the company’s stock after acquiring an additional 452,627 shares during the quarter. Nuveen Asset […] - 2025-05-27 06:05:03

Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease

(RTTNews) - Viridian Therapeutics Inc. (VRDN) announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug or "veli", an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye - 2025-05-20 08:29:45

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Increased by Barclays PLC

Barclays PLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 25.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 157,860 shares of the company’s stock after buying an additional 32,463 shares during the quarter. Barclays PLC’s holdings in Viridian Therapeutics were worth $3,027,000 at the end of the […] - 2025-04-30 05:50:47

Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts […] - 2025-04-28 03:08:56

Geode Capital Management LLC Purchases 165,669 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Geode Capital Management LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 11.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,658,980 shares of the company’s stock after acquiring an additional 165,669 shares […] - 2025-04-17 04:52:50

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Holdings Lifted by Corebridge Financial Inc.

Corebridge Financial Inc. grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,336 shares of the company’s stock after buying an additional 2,878 shares during […] - 2025-04-07 04:32:49

Comparing Viridian Therapeutics (NASDAQ:VRDN) & ACI Global (OTCMKTS:ACGJ)

ACI Global (OTCMKTS:ACGJ – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Profitability This table compares ACI Global and Viridian […] - 2025-04-03 03:08:55

Swiss National Bank Boosts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Swiss National Bank grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 112,600 shares of the company’s stock after buying an additional 4,500 shares during the quarter. Swiss National Bank’s holdings in Viridian Therapeutics were worth $2,159,000 at the end of the […] - 2025-03-28 05:52:52

Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $35.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The […] - 2025-02-26 04:23:00

R Squared Ltd Takes $26,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

R Squared Ltd acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,340 shares of the company’s stock, valued at approximately $26,000. A number of other hedge funds have also […] - 2025-02-05 06:42:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc VRDN holdings

Date	Number of VRDN Shares Held	Base Market Value of VRDN Shares	Local Market Value of VRDN Shares	Change in VRDN Shares Held	Change in VRDN Base Value	Current Price per VRDN Share Held	Previous Price per VRDN Share Held
2025-09-26 (Friday)	39,121	USD 789,853	USD 789,853
2025-09-25 (Thursday)	39,121	USD 746,429	USD 746,429	0	USD -16,431	USD 19.08	USD 19.5
2025-09-24 (Wednesday)	39,121	USD 762,860	USD 762,860
2025-09-17 (Wednesday)	38,867	USD 723,704	USD 723,704	0	USD -1,554	USD 18.62	USD 18.66
2025-09-16 (Tuesday)	38,867	USD 725,258	USD 725,258
2025-09-12 (Friday)	38,615	USD 728,665	USD 728,665
2025-09-11 (Thursday)	38,615	USD 758,785	USD 758,785	504	USD 3,806	USD 19.65	USD 19.81

Share Trades of VRDN by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-09-11	BUY	504			19.650*		16.54
2025-08-21	SELL	-250			18.020*		16.53 Profit of 4,132 on sale
2025-07-31	BUY	750			17.520*		16.51
2025-06-30	SELL	-500			13.980*		16.53 Profit of 8,265 on sale
2025-06-25	SELL	-250			14.700*		16.57 Profit of 4,143 on sale
2025-06-20	SELL	-500			14.720*		16.61 Profit of 8,306 on sale
2025-05-23	BUY	250			13.570*		16.94
2025-05-19	SELL	-250			12.820*		17.06 Profit of 4,265 on sale
2025-05-15	SELL	-750			12.620*		17.14 Profit of 12,851 on sale
2025-05-12	SELL	-250			13.120*		17.25 Profit of 4,313 on sale
2025-05-09	SELL	-250			12.390*		17.30 Profit of 4,324 on sale
2025-04-30	SELL	-250			13.550*		17.59 Profit of 4,397 on sale
2025-04-24	SELL	-500			13.560*		17.76 Profit of 8,878 on sale
2025-04-17	SELL	-250			13.130*		17.99 Profit of 4,498 on sale
2025-04-15	SELL	-750			12.800*		18.11 Profit of 13,579 on sale
2025-04-14	SELL	-750			13.300*		18.16 Profit of 13,619 on sale
2025-04-09	SELL	-1,000			11.790*		18.38 Profit of 18,377 on sale
2025-04-07	SELL	-1,757			11.780*		18.54 Profit of 32,573 on sale
2025-04-04	SELL	-2,510			11.990*		18.62 Profit of 46,727 on sale
2025-03-31	BUY	251			13.480*		18.82
2025-03-19	SELL	-502			15.430*		19.24 Profit of 9,658 on sale
2025-03-14	SELL	-1,506			15.920*		19.39 Profit of 29,200 on sale
2025-03-13	SELL	-504			15.810*		19.44 Profit of 9,798 on sale
2025-03-12	SELL	-8,568			16.650*		19.48 Profit of 166,910 on sale
2025-03-07	SELL	-504			15.940*		19.64 Profit of 9,901 on sale
2025-03-06	SELL	-756			15.880*		19.70 Profit of 14,895 on sale
2025-03-03	SELL	-252			14.410*		19.93 Profit of 5,023 on sale
2025-02-28	BUY	14,727			15.530*		20.00
2025-02-26	SELL	-209			15.530*		20.16 Profit of 4,213 on sale
2025-02-25	SELL	-627			15.540*		20.24 Profit of 12,690 on sale
2025-02-18	BUY	1,045			15.850*		20.62
2025-02-13	BUY	209			17.020*		20.86
2025-02-12	BUY	209			17.470*		20.93
2025-02-11	BUY	627			17.860*		20.99
2025-02-06	BUY	1,881			18.510*		21.18
2025-01-27	BUY	209			18.910*		21.56
2024-12-30	BUY	1,045			19.540*		21.86
2024-12-06	BUY	836			19.720*		22.09
2024-12-05	BUY	209			19.630*		22.17
2024-12-04	BUY	1,040			19.960*		22.25
2024-11-29	BUY	1,040			21.550*		22.42
2024-11-27	BUY	832			21.870*		22.47
2024-11-26	BUY	208			21.910*		22.49
2024-11-25	BUY	5,819			21.030*		22.56
2024-11-21	BUY	950			19.620*		22.84
2024-11-20	BUY	570			19.790*		23.01
2024-11-18	BUY	2,280			20.340*		23.35
2024-11-12	BUY	1,520			22.430*		23.41
2024-11-08	BUY	950			25.210*		23.28
2024-11-07	BUY	2,835			24.710*		23.17
2024-11-06	BUY	378			24.270*		23.08
2024-10-31	BUY	189			21.570*		23.38

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of VRDN

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer